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Abstract The evolution of adenosine 3P,5P-cyclic monophos-
phate (cAMP) levels was investigated in synchronised tobacco
BY-2 cells by virtue of a method based on immunoaffinity
purification and analysis on electrospray tandem mass spectrom-
etry. A transient peak in cAMP content was observed during the
S and G1 phases of the cell cycle. Application of the
prostaglandin inhibiting drug indomethacin at early S phase
resulted in the loss of the cAMP peak in S phase and inhibited
mitotic division. This inhibition of cAMP accumulation suggests
the presence of a prostaglandin-dependent adenylyl cyclase
activity, analogous to animal cyclases. A potential role for
cAMP during the plant cell cycle is postulated.
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1. Introduction
Adenosine 3P,5P-cyclic monophosphate (cAMP) is an im-
portant regulatory molecule in a vast multitude of cellular
processes. For example, cAMP has been implicated in catab-
olite repression [1], chemotaxis [2], and hormone action [3].
Cyclic AMP is thought to play a role in cell cycle control in
animal and fungal systems. Its concentration £uctuates during
cell cycle progression [4] and depending on the cell type it
exhibits stimulatory or inhibitory e¡ects on cell proliferation
[5,6]. A transient rise in cAMP before the onset of S phase is
believed to be part of a series of events leading to DNA syn-
thesis [7]. Cyclin A, cyclin D and cyclin E expression are
a¡ected by cAMP [8^11]. A direct phosphorylation of cyclin
D1 in the cyclin box by a cAMP-dependent protein kinase is
thought to regulate its activity [12]. Forskolin and 8-Br-cAMP
inhibit cyclin A- and cyclin E-dependent histone H1 kinase
activity in an astrocytic cell line [11]. The Saccharomyces ce-
revisiae cell cycle is highly regulated by the RAS/cAMP signal
transduction pathway as well [13,14]. Cyclic AMP was shown
to be a key regulator of the circadian rhythm driven cell cycle
of the unicellular alga Euglena gracilis [15,16].
Data on the presence of cAMP and its metabolism in vas-
cular plants are continuously coming forth. However, the
physiological importance of cAMP in plants remains a matter
of debate [17^19]. The plant cell cycle seems mechanistically
similar to that of other eukaryotes and most of the key reg-
ulators of the animal cell cycle are conserved in higher plants
[20^24]. This prompted us to investigate a comparable func-
tion for cAMP in the cell cycle of higher plants.
As an experimental system tobacco BY-2 cells were chosen
because of their high growth rate, homogeneity and synchro-
nisation potential [25]. The role of cAMP in cell cycle pro-
gression was studied by addition of indomethacin, a potent
inhibitor of prostaglandin synthesis [26] reported to inhibit
adenylyl cyclase in animal cells [27]. In contrast to animal
systems where the relationship between indomethacin treat-
ment and cAMP metabolism has been well studied, its inhib-
itory action on both cAMP synthesis and cell cycle, as de-
scribed in this paper, has never been reported in plant cells
before.
2. Materials and methods
2.1. Culture maintenance, synchronisation and sampling
Tobacco BY-2 cell cultures were maintained as described by Nagata
et al. [25]. Depending on the aim of the experiment either an aphidi-
colin block or a sequential aphidicolin^propyzamide block was per-
formed. Ten to ¢fteen ml of stationary culture were transferred to 100
ml of MS medium containing 5 Wg/ml aphidicolin (Sigma). After 24 h
cells were extensively washed and released in 100 ml of fresh medium.
Unless stated otherwise aphidicolin block was used as the default
synchronising tool. Propyzamide (1.54 Wg/ml) was added during G2
phase (about 4 h after aphidicolin release) and removed by extensive
washing when almost all cells were synchronised in prometaphase.
2.2. Mitotic index, Northern analysis, nuclei isolation and £ow
cytometry
Samples for mitotic index, Northern analysis and £ow cytometric
analysis were gathered every hour. To determine the mitotic index,
cells were ¢xed with ethanol/acetic acid (3:1, v/v) and stored at 4‡C
until analysis (within 24 h). Fixed cells were stained with 5 WM DAPI
(4P,6-diamidino-2-phenylindole) and analysed using a £uorescent mi-
croscope (Leitz, Germany) by counting the number of nuclei (300
cells) in late prophase to telophase. Viability tests were done by add-
ing FDA (£uorescein di-acetate) at a concentration of 5 Wg/ml cell
suspension culture.
Total RNA was prepared using the TRIzol reagent (Gibco/BRL)
according to the manufacturer’s instructions. RNA blots were hybri-
dised at 65‡C in 500 mM NaPi bu¡er containing 7% SDS, 1% BSA
and 1 mM EDTA [28] to random primed 32P probes corresponding to
the coding region of the Arabidopsis thaliana H4A748 gene [23]. Tran-
script levels were quanti¢ed from the blots using a PhosphorImager
(Molecular Dynamics).
Nuclei were puri¢ed from the cells by enzymatic treatment accord-
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ing to [29] and stored at 4‡C until further analysis by £ow cytometry.
On the day of analysis, isolated nuclei were treated with RNAse A,
stained with propidium iodide (50 Wg/ml) and analysed with a FACS
scan £ow cytometer.
2.3. Extraction and puri¢cation of cAMP
Samples for cAMP determination were collected every 30 min. The
cells were left to sediment on ice and the supernatant was carefully
removed. Samples were frozen in liquid nitrogen and kept at 380‡C
until analysis. Seven to eight hundred mg of cells were ground with a
mortar and pestle in liquid nitrogen and homogenised in an ice-cold
mixture of methanol/chloroform/1 M formic acid (12:5:3; v/v) con-
taining 1000 Bq [3H-2P,8]-3P,5P-cAMP as an internal standard. The
samples were immunoa⁄nity-puri¢ed according to Roef et al. [30]
and stored at 320‡C until further analysis.
2.4. Cyclic AMP identi¢cation and quanti¢cation
Immunoa⁄nity-puri¢ed samples were dissolved in 25 Wl of the mo-
bile phase and injected into the LC-UV-MS/MS combination consist-
ing of a Kontron 465 HPLC Autosampler, the Kontron 325 HPLC
pump, the Kontron 332 UV-detector (Kontron Instruments, Italy)
and the Quattro II tandem mass spectrometer (Micromass, UK).
Samples were eluted using ion suppression conditions (0.25% HAc,
9% MeOH, pH 3.5) on a microbore HPLC column (C18 Adsorbo-
sphere, 250U2.1 mm, Alltech Associates Inc., Belgium) using a £ow
rate of 200 Wl/min. Electrospray mass spectra were recorded in neg-
ative ionisation mode with the probe tip kept at 33 kV, a cone
voltage of 32 V and a source temperature of 125‡C. Data were inter-
preted using the accompanying MassLynx Mass Spectrometric Data
Handling System for Windows (Micromass, UK). Quanti¢cation was
carried out by multiple reaction monitoring (MRM) using the diag-
nostic transition 328C134 [31]. Final cAMP concentrations in plant
cells were calculated from the area of the MRM ion chromatogram.
They were expressed as picomole 3P,5P-cAMP per gram of fresh
weight of BY-2 cells.
3. Results
3.1. Cyclic AMP levels in synchronised TBY-2 cells
Cyclic AMP content was measured in aphidicolin synchron-
ised tobacco BY-2 cells (Fig. 1, upper part). Cell cycle pro-
gression was monitored by determination of mitotic index,
histone 4 (H4) gene expression and £ow cytometry (Figs. 1
and 3). BY-2 cell suspensions synchronised with aphidicolin
generally show a peak in mitotic index of about 40% at 6 to
7 h after release. By 9 to 10 h of culture all cells have reached
G1 phase (Fig. 3, t0 AB through t10 AB). Cyclic AMP levels
showed distinct peaks during S phase (maximum H4 mRNA
expression) and G1 phase (Fig. 1, upper part). No additional
peaks above a calculated detection limit of approximately
5 pmol/gfw appeared at other stages of the cell cycle.
Cyclic AMP £uxes during cell cyclic were further docu-
mented in cells that were sequentially treated with aphidicolin
and propyzamide (Fig. 2). The sequential aphidicolin-propyz-
amide block resulted in a high synchronisation at prometa-
phase with a mitotic index reaching 90% (Fig. 2). H4 mRNA
steady state levels were most abundant 9 h after propyzamide
release. Cells synchronised by the double aphidicolin-propyz-
amide block again showed elevated cAMP levels in S phase
coinciding with H4 mRNA expression (Fig. 2). The rise in
cAMP noticed during G1 phase in aphidicolin-treated cells
was less apparent here.
3.2. Indomethacin blocks BY-2 cells at G2 phase of the cycle
The in£uence of indomethacin on tobacco BY-2 cell cycle
was investigated in cells supplied with 10 Wg indomethacin/ml
immediately after aphidicolin release. Cell cycle progression
was analysed by £ow cytometry (Fig. 3) and mitotic index
(Fig. 4a). DNA content distribution revealed cells passed
through S phase to be subsequently retained in G2 (Fig. 3:
t1 IM through t7 IM) whereas control cells progressed
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Fig. 1. Cyclic AMP content (solid bars) in aphidicolin synchronised
cells (dashed line represents the detection limit). a9a : Mitotic in-
dex; b- - -b : H4-mRNA levels. The approximate duration of the
di¡erent phases of the cycle is represented in the lower part (u : AB
release).
Fig. 2. Cyclic AMP content (898) in aphidicolin-propyzamide
synchronised cells. a9a : Mitotic index; b- - -b : H4-mRNA levels.
The approximate duration of the di¡erent phases of the cycle is rep-
resented in the lower part (u : PZ release).
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through S-G2-M and eventually reached G1 (Fig. 3, lane 1;
Fig. 4a). Some indomethacin treated cells eventually showed
mitosis 9 h after aphidicolin release and passed to G1 phase
(Fig. 3: t9 IM and t10 IM; Fig. 4). The fact that indomethacin
treated cells eventually do engage in mitosis and escape into
G1 suggests that indomethacin was not toxic at the concen-
trations used. This observation was con¢rmed by viability
staining (data not shown).
3.3. Inhibition of cAMP accumulation by indomethacin
In animal systems, indomethacin acts on the cell cycle
through the indirect inhibition of adenylyl cyclase activity
[27]. We therefore investigated the behaviour of cAMP accu-
mulation during S phase as a response to indomethacin addi-
tion. Our results show that the S-phase associated rise in
cAMP was completely abolished in cells treated with indo-
methacin (Fig. 4b). Non-treated cells showed a marked in-
crease in cAMP content during S phase with peak values of
approximately 30 pmol/gfw at 2 h after release. In cells treated
with indomethacin these levels were reduced to values of
around 5 to 7 pmol per gram fresh weight. Since indometha-
cin interferes with mitosis as well, a potential role for cAMP
in cell cycle progression in plant systems is postulated. In
order to determine the necessity of cAMP for proper cell cycle
progression, cAMP was delivered to indomethacin-treated
cells and cell cycle progression and mitotic division were ex-
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Fig. 3. Flow cytometric analysis of DNA content in indomethacin
treated cells. Lane 1: control cells; lane 2: IM treated cells. The dot
plot top represents a cytogram of the width vs. area £uorescence of
the DNA signal of an indomethacin treated sample (t10 IM). Aggre-
gates were excluded from real G2/M phase nuclei by £uorescence
pulse shape analysis, based on the fact that aggregates exhibit a
larger pulse width. The trail of low £uorescence signals towards the
origin represents nuclear debris. Only dots within the region dis-
played are included in the histogram analysis.
Fig. 4. a: Mitotis in indomethacin treated cells. a9a : Control
cells ; b9b : indomethacin treated cells. b: Inhibition of cAMP ac-
cumulation by indomethacin during S phase. 797 : Control cells ;
898 : indomethacin treated cells.
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amined. The addition of cAMP to indomethacin-inhibited
cells failed to restore mitosis. The addition of more mem-
brane-permeable cAMP analogues (8-Br-cAMP and dibutyr-
yl-cAMP) could not rescue indomethacin-arrested cells either
(Fig. 5).
4. Discussion
The evolution of cAMP levels during the plant cell cycle
was studied in tobacco BY-2 cells synchronised by means of
aphidicolin treatment or sequential aphidicolin-propyzamide
block. Two important observations were made. It appears
that cAMP levels are stringently controlled during the tobacco
BY-2 cell cycle and that both cAMP accumulation and mito-
sis are inhibited upon indomethacin treatment.
Our data show that £uctuations in intracellular cAMP lev-
els of synchronised tobacco BY-2 cells are tightly connected to
cell cycle progression. Cyclic AMP peaks were observed in S
phase, and to a lesser extent in G1 phase, in cells synchronised
with either the aphidicolin or aphidicolin-propyzamide meth-
od. As these cAMP peaks were observed at the same stages of
the cell cycle in both synchronisation systems, they are gen-
uinely cell cycle dependent and not, for instance, stress in-
duced.
This is to our knowledge the ¢rst time a cell cycle regulated
cAMP accumulation is shown in a higher plant. Cell cycle
dependent £uctuations of cAMP have been observed in a
number of animal systems [4,7,32] and fungi [13,14]. Gener-
ally, a peak in cAMP is observed during G1 phase. This peak
is believed to be involved in the initiation of DNA synthesis.
A second peak during G2 seems to be correlated to the onset
of mitosis [32]. Similar surges in cAMP in G1 and at the onset
of mitosis were observed in the unicellular alga Euglena gra-
cilis. They are believed to synchronise cell division of this
lower plant with circadian rhythm by guiding cells through
G1/S and G2/M boundaries [33]. The £uctuations in cAMP
levels we observed during the tobacco BY-2 cell cycle are very
reminiscent of the ones encountered in mastocytoma P-815
cells [4], with peak values of cAMP in S phase and G2 phase,
and to a lesser extent in G1. The peaks at S and G2 are
probably induced by PGE1. Although the signi¢cance of
the peak at S phase is unclear the tight control of cAMP
levels during tobacco BY-2 cell cycle strongly argues for an
important role of cAMP in cell cycle progression in higher
plants.
Since an indomethacin-induced inhibition of mitosis was
recognised in our TBY-2 cells, this study is to our knowledge
the ¢rst to show such susceptibility of a plant system to in-
domethacin. In lymphocytes the indomethacin-induced arrest
of the cell cycle is caused by the inactivation of a prostaglan-
din-induced adenylyl cyclase activity [27]. A similar relation-
ship between indomethacin and cAMP metabolism seems to
exist in tobacco BY-2 cells. The observed inhibition of cAMP
accumulation in response to indomethacin treatment is indeed
indicative for the presence of a prostaglandin-dependent ad-
enylyl cyclase activity in tobacco BY-2 cell. Such connection
has never been reported before for plant systems. The mere
existence of prostaglandin metabolism and de¢nitely cAMP
metabolism in plants is actually not widely accepted yet
[17,34]. Addition of prostaglandins, or prostaglandin-like
compounds, to indomethacin blocked cells and subsequent
analysis of cAMP content and adenylyl cyclase activity should
provide clues as to whether the same signal transduction path-
way is active in the plant cell.
The observation that indomethacin simultaneously prevents
cAMP accumulation and inhibits mitosis in the tobacco BY-2
system strengthened our belief in the need for cAMP for
proper cell cycle progression. However, experiments set up
to rescue indomethacin blocked cells by addition of exogenous
cAMP failed. This cannot be explained by poor uptake of
cAMP into the cells. Data not shown in Section 3 indicated
that 3H-cAMP, when supplied to the culture medium at a
concentration of 1 WM, did accumulate in the cells to an
extent were it is able to perform its action. In addition, dibu-
tyryl-cAMP and 8-Br-cAMP were equally inadequate in res-
cuing indomethacin-blocked cells. We therefore conclude that
an increase in intracellular cAMP alone cannot counteract the
indomethacin block. Many reports suggest that the cAMP
peak at G1/S must be transient to allow for proper cell cycle
progression in animal cells. A rise in cAMP is necessary for
the onset of DNA synthesis but the persistent elevation of
cAMP supposedly blocks initiation of S phase or prematurely
terminates DNA replication [7,32]. This was also shown for
Euglena gracilis. Sustaining the G1 peak by addition of exog-
enous cAMP caused a delay in the progression of cells
through S phase [33]. The failure to rescue indomethacin
blocked cells by addition of cAMP might re£ect the presence
of a similar mechanism in tobacco cells.
In animal systems, indomethacin is a pleiotropic drug act-
ing primarily on prostaglandin synthesis, and consequently on
adenylyl cyclase. In this report we have provided evidence
indicative for the presence of a similar pathway in TBY-2
cells. But in some instances indomethacin appears to act
downstream from cAMP too by directly a¡ecting cAMP-de-
pendent protein kinase activity [35]. In addition, indomethacin
might also exert an e¡ect on cell cycle following from its
impact on signal transduction pathways branching out from
other prostaglandin regulated events (with cyclic AMP just
being one of the second messengers a¡ected). In both cases
the sole addition of cAMP will prove ine¡ective in restoring
indomethacin induced inhibition of mitosis. Evidence for a
positive need of cAMP for proper cell cycle progression
should therefore come from experiments in which cAMP ac-
cumulation is inhibited by means of methods independent of
prostaglandin metabolism. At present, the tools to do so are
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Fig. 5. Mitotis in indomethacin treated cells. Salvage by cAMP and
cAMP-analogues.
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not at hand. Chemicals exist that inhibit adenylyl cyclase ac-
tivity in animal systems but none of them have been ad-
equately characterised in plant systems. Future work will pur-
sue the identi¢cation of such compounds and their in£uence
on the plant cell cycle.
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